Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab

NCT00477893 is registered in ClinicalTrials.gov with Glostrup University Hospital, Copenhagen as lead sponsor.

NCT NCT00477893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00477893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab
Lead sponsor
Glostrup University Hospital, Copenhagen
Phase
Phase 4
Overall status
Unknown status
Start date
February 28, 2006
Completion date
January 31, 2013
Enrollment
52 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

spondyloarthritis